To this end, the activation of the RAS/MAPK or JAK/STAT pathway by cytokines secreted by the BME can allow for the survival of FLT3-mutated AML blasts treated with FLT3-inhibitors when they are hosted in the BM niche [88]. Here, FLT3 is linked to acute myeloid leukemia.